US Acute Myeloid Leukemia Market to 2028

Segmented by Treatment Type (Chemotherapy, Targeted Therapy, Hormone Therapy, Immunotherapy, and others) by End-User Industry (Hospitals, Homecare, Specialty Centers, Pharmacies, and others), by Region-(North, East, West and South)

Region:North America

Author(s):Geetanshi Chugh

Product Code:KROD234

Download Sample Report download
Buy the Full ReportStarting from $4750
Published on

September 2023

Total pages


About the Report

About the Report

Market Overview:

The US Acute Myeloid leukemia Market is expected to witness more promising growth due to advancement in treatment approaches, increases healthcare costs and expenditure, growing investments in Research and Development, and a constant growth in population. Advancement in therapeutic approaches, including targeted therapies, immunotherapies, checkpoint inhibitors, and personalized medicines, have revolutionized AML treatment, boosting patient satisfaction and reducing side effects.

US Acute Myeloid Leukemia Market Revenue

Rising healthcare expenditures have expanded access to specialized diagnostics and treatments, with a surge in medical insurers facilitating affordability. Investments in R&D have resulted in innovative product launches, heightening consumer satisfaction and propelling market expansion. The surging US population has led to a higher prevalence of AML cases, intensifying demand for treatment options, diagnostic services, and supportive care. This demographic trend accelerates the urgency for accessible, advanced therapies, fostering a multifaceted demand that catalyzes market growth and stimulates further research endeavors. With a projected CAGR of 10.5% during the forecast period (2022-2028), the US AML market stands poised for robust progression, underpinned by its convergence of medical innovation, financial accessibility, and population dynamics.

The ecosystem of US Acute Myeloid Leukemia Market is characterized by dynamic interplay of pharmaceutical giants, diagnostic companies, hospitals that are providing treatment for Acute Myeloid leukemia, and health insurance providing companies that help in getting easy and affordable treatment to the diagnosed patients. The top dominant companies in the pharmaceutical sector which are driving the market growth are Pfizer Inc., Bristol Myers Squibb, Novartis, and AbbVie. The top Diagnostic companies leading the market are Abbott Laboratories and Roche Diagnostics. The leading hospital in the market providing quality treatment are MD Anderson Cancer Center and Mayo Clinic. The health insurance companies helping the diagnosed patients are United Health Group and Anthem Inc.

Ecosystem of Top Players in US Acute Myeloid Leukemia Market

US Acute Myeloid Leukemia Market Analysis

  • Acute Myeloid Leukemia represents 1% of all the new cancer diagnoses found in US and has a five-year survival rate of around 29%. According to the American Society of Clinical Oncology in 2021, around 20,250 people were diagnosed with Acute Myeloid Leukemia and it is estimated that there will be around 59,600 new cases and around 23,709 deaths from Leukemia of all kinds in 2023.
  • New and advanced technologies are creating innovations such as targeted therapies, checkpoint inhibitors, personalized medicines, and immunotherapies, which help to enhance treatment efficiency and moreover it minimizes the side effects of treatment, leading to high patient satisfaction, survival, and remission rates.
  • Increasing healthcare expenditure leading to greater access to advanced technologies, specialized treatments, and therapies. The rise in healthcare expenditure is a result of increased healthcare costs as the cost of healthcare and medical services increase at a faster rate compared to the cost of other goods and services.
  • As a rescue to high healthcare services cost, heath insurance companies come to the rescue, health insurance provides diagnosed patients with affordable treatment covers and provides improved access to healthcare services without being burdened by full cost of treatments.
  • Increased investments in the R&D process initiates new product launches and effective treatment approaches which drive the growth of US acute Myeloid Leukemia Market. The research industry of US accounted for 70% of US health and medical investment in 2020.

Key Trends by Market Segment:

By Treatment Type: In terms of treatment type the market is segmented into chemotherapy, targeted therapy, hormone therapy, Immunotherapy, and others. In 2022, there is a rise in the dominance of targeted therapy, as unlike traditional chemotherapy, targeted therapy focuses on specific molecule markers within cancer cells, which minimize the damage to the healthy cells. The targeted therapy offers improved results with fewer side effects.

US Acute Myeloid Leukemia Market Revenue By Treatment Type

By End-User Industry: The market is segmented by End-User industry into hospitals, homecare, specialty centers, Pharmacies, and others. Among these specialty centers were the dominant end-user industry in 2022, as they provide specialized expertise, cutting-edge treatments, and supportive care for Acute Myeloid Leukemia patients. Hospitals also play a crucial role in the initial stages but specialty centers provide focused attention and advanced therapies.

US Acute Myeloid Leukemia Market Segmentation By End-User Industry

By Geography: The US Acute Myeloid Leukemia Market is Segmented into North, East, South, and West region of US. In 2022, the Northern region of US was the most dominant region in Acute Myeloid Leukemia Market.

The northern region of US is home to several renowned medical and research institutions. These institutions have strong oncology departments. They have significant investments in research and development, and driving advancements in AML treatment.

Additionally, the northern region of US has a higher population density which contributes to higher number of Acute Myeloid Leukemia cases and greater access to specialized medical services.

US Acute Myeloid Leukemia Market Regional Analysis

Competitive Landscape:

  • The US Acute Myeloid Leukemia Market is characterized by intense competition and features numerous prominent participants who are involved Acute Myeloid Leukemia Market. Among the leading contenders in the US Acute Myeloid Leukemia Market are Pfizer Inc., Bristol Myers Squibb, Novartis, and AbbVie, Amgen, Janssen Pharmaceuticals, Takeda Pharmaceuticals
  • The US Acute Myeloid Leukemia Market features a dynamic competitive landscape with a mix of pharmaceutical giants, biotechnology innovators, diagnostics centers, health insurance companies, and healthcare institutions.
  • Intense competition in the market is driving a surge in technology adoption. Players are embracing cloud-based solutions, AI-driven analytics, and digital platforms to enhance efficiency, streamline processes, and offer personalized loan experiences, fostering a tech-driven competitive edge.
  • Academic medical centers and specialized hospitals offer comprehensive patient care and innovative clinical trials. Collaborations between these entities further drive innovation, with diagnostic companies like Abbott and Roche enhancing AML detection. The landscape is propelled by advancing treatments, personalized approaches, and research breakthroughs. Ultimately, the competition centers around providing more effective, safer, and accessible treatments while responding to the evolving needs of AML patients and reshaping the trajectory of the market.

Competitive Landscape of US Acute Myeloid Leukemia Market

Recent Developments:

      • December 2017, Pfizer announced that, the Food and Drug Administration (FDA) of US approved Bosutinib for the treatment of patients with chronic myelogenous leukemia (CML).
      • In January 2020 Bristol Myers Squibb received the US FDA’S approval for Onureg for the treatment of adult patients with AML. Moreover, Novartis AG is developing a combination drug (MBG453, Venetoclax, Azacitidine) for the treatment of Acute Myeloid Leukemia, which is in phase 2 of clinical trials.
      • June 2021, Bristol Myers Squibb received approval from European Commission for Onureg, a Frontline oral maintenance therapy for adult patients with acute Myeloid Leukemia who achieved their first complete remission (CR) or CR with incomplete blood count recovery following intensive induction chemotherapy.
      • In December 2022, Pfizer announced its collaboration with Gero’s machine learning technology platform to discover potential therapeutic targets for fibrotic using large-scale human- based data.

Future Outlook:

      • US Acute Myeloid Leukemia Market is expected to show increasing and is expected to grow at a CAGR of 10.5% from 2022 to 2028 with advancement in treatment approaches, increases healthcare costs and expenditure, growing investments in Research and Development, and a constant growth in population.
      • The ongoing development of targeted therapies, immunotherapies, and personalized medicines is expected to further elevate treatment outcomes by minimizing side effects and enhancing efficacy. This precision-focused approach will likely shape the standard of care, optimizing patient experiences and survival rates.
      • The expansion of telehealth and remote monitoring will improve patient access to specialized care and clinical trials. As healthcare policies evolve, equitable access to cutting-edge treatments may become more attainable.
      • Patient-centric care models, alongside growing awareness and patient advocacy efforts, will influence treatment decision-making and ensure holistic support. Overall, the Acute Myeloid Leukemia market's trajectory is characterized by improved treatments, increased survival rates, and a commitment to reshaping the future of Acute Myeloid Leukemia are through innovation, collaboration, and patient-centric approaches.

Scope Of The Report

Scope of the Report

US Acute Myeloid Leukemia Market Segmentation

By Treatment Type


Targeted Therapy

Hormone Therapy



By End User Industry



Specialty Centers



By Geography





Customize This Report for You
Need a Specific Data? Like: Pricing Analysis Competitor Analysis Benchmarking Data Business Planning
Customize Now!



Key Target Audience – Organizations and Entities Who Can Benefit by Subscribing This Report:

  • Medical Professionals
  • Pharmaceutical and Biotech Companies
  • Research Institutions
  • Hospital and Clinics
  • Healthcare Administrators and Insurers
  • Diagnostics companies
  • Government Bodies & Regulating Authorities
  • Industry Associations
  • Potential Market Entrants

Time Period Captured in the Report:

  • Historical Period: 2017-2022
  • Base Year: 2022
  • Forecast Period: 2022-2028


Major Players Mentioned in the Report:

  • Pfizer Inc.
  • Bristol Myers Squibb
  • Novartis AG
  • AbbVie
  • Amgen
  • Janssen Pharmaceuticals
  • Takeda Pharmaceuticals

Table of Contents

Table of Contents

1. Executive Summary

2. US Acute Myeloid Leukemia Market Overview

2.1 Taxonomy of the Market

2.2 Industry Value Chain

2.3 Ecosystem

2.4 Government Regulations/Initiatives for the Market 

2.5 Growth Drivers of the US Acute Myeloid Leukemia Market

2.6 Issues and Challenges of the US Acute Myeloid Leukemia Market

2.7 Impact of COVID-19 on the US Acute Myeloid Leukemia Market

2.8 SWOT Analysis

3. US Acute Myeloid Leukemia Market Size, 2017 – 2022

4. US Acute Myeloid Leukemia Market Segmentation

4.1 By Treatment Type, 2017 - 2022

4.2 By End User Industry, 2017 - 2022

4.3 By Regional Split (North/East/West/South), 2017 - 2022

5. Competitive Landscape

5.1 Mergers and Acquisitions, Joint Ventures, Collaborations, and Agreements

5.2 Strategies Adopted by Leading Players

5.3 Company Profiles 

5.3.1 Pfizer Inc.

5.3.2 Bristol Myers Squib

5.3.3 Novartis AG

5.3.4 AbbVie

5.3.5 Amgen

5.3.6 Janssen Pharmaceuticals

5.3.7 Takeda Pharmaceuticals

6. US Acute Myeloid Leukemia Market Future Market Size, 2022 – 2028

7. US Acute Myeloid Leukemia Market Future Market Segmentation

7.1 By Treatment Type, 2022 - 2028

7.2 By End-User Industry, 2022 - 2028

7.3 By Regional Split (North/East/West/South), 2022 - 2028

8. Analyst Recommendations

9. Research Methodology

10. Disclaimer

11. Contact Us

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Research Methodology

Research Methodology

Step: 1 Identifying Key Variables: 

Ecosystem creation for all the major entities and referring to multiple secondary and proprietary databases to perform desk research around the market to collate industry-level information.

Step: 2 Market building:

Collating statistics on Acute Myeloid Leukemia over the years, penetration of and pharmaceutical units to compute revenue generated for the Acute Myeloid Leukemia market. We will also review service quality statistics to understand revenue generated which can ensure accuracy behind the data points shared.

Step: 3 Validating and Finalizing:

Building market hypotheses and conducting CATIs with industry experts belonging to different companies to validate statistics and seek operational and financial information from company representatives.

Step: 4 Research output:

Our team has approached multiple treatment-providing channels and understands the nature of product segments and sales, consumer preference, and other parameters, which will support us validate statistics derived through bottom to top approach from US Acute Myeloid Leukemia Market.

Research Methodology for US Acute Myeloid Leukemia Industry

Research Methodology for US Acute Myeloid Leukemia Market

Frequently Asked Questions

Frequently Asked Questions

01 What companies are working on US acute myeloid leukaemia?

Bristol-Myers Squibb Co, Les Laboratoires Servier SAS, Novartis AG, Pfizer Inc, AbbVie Inc, and Ascentage Pharma Group International are some of the leading companies in the AML market. 

02 How big is the US Acute Myeloid Leukemia Market?  

The US cute Acute Myeloid Leukemia Market is valued at $0.49 Bn in 2022. 

03 What is the new FDA-approved drug for AML?

On July 20, the FDA approved the use of the drug quizartinib (Vanflyta) in combination with chemotherapy for those with AML who had a particular FLT3 gene mutation. When AML is diagnosed, FLT3 genetic alterations are frequently present.

04 What is the first-line drug for AML?

Quizartinib is used in conjunction with conventional cytarabine and anthracycline induction and cytarabine consolidation, as well as maintenance monotherapy after consolidation chemotherapy, for the treatment of adult patients. 

05 What are the major players in the US AML market?

Some prominent players in the US AML market are Pfizer Inc., Bristol Myers Squib, Novartis AG, AbbVie,  Amgen, Janssen Pharmaceuticals, and Takeda Pharmaceuticals. 

06 What is the future growth rate of the US AML Market?

The US Acute Myeloid Leukemia Market is expected to grow at a CAGR of 10.5 % from 2023-2028.

👋 Don't Miss Out

Pre-book this report and get huge discount

Buy the Full ReportStarting from $4750
Research Reports Trusted By 2500+ Brands

Why Buy From US?

Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022